Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

583
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
583
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.9K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.9K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

467
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
467
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

418
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
418
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

451
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
451

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Additive Value of Transesophageal Echocardiography Without Sedation for Diagnosis of a High-Risk Patent Foramen Ovale.

Korean circulation journal·2026
Same authorSame journal

A Decade of Transformation in Stroke Care in South Korea (2013-2023): Increasing Ambulance Use but Persistent Prehospital Delay and Reversing Mortality Trends.

Journal of stroke·2026
Same author

Comprehensive Prestroke Risk Factor Control and Functional Outcomes After Acute Ischemic Stroke.

Journal of the American Heart Association·2026
Same author

Dynamics of tumor ecosystems and microbiome in response to neoadjuvant ABFOLFOX treatment in patients with unresectable colorectal cancer with liver metastasis.

Genome medicine·2026
Same author

Differential stress-induced ischemic electrocardiographic changes in acute versus stable coronary syndromes with severely reduced fractional flow reserve (≤0.60).

International journal of cardiology. Heart & vasculature·2026
Same author

Dental caries risk in patients with chronic airway diseases using dry powder inhalers: a retrospective cohort study.

BMC oral health·2026

Related Experiment Video

Updated: Apr 1, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.8K

Statins in Acute Ischemic Stroke: A Systematic Review.

Keun-Sik Hong1, Ji Sung Lee2

  • 1Department of Neurology, Inje University Ilsan Paik Hospital, Goyang, Korea.

Journal of Stroke
|October 7, 2015
PubMed
Summary

Statins may improve outcomes for acute ischemic stroke (AIS) patients by reducing stroke severity and mortality. Further randomized trials are needed to confirm these benefits, especially regarding hemorrhagic transformation risks.

Keywords:
Acute ischemic strokeMortalityOutcomeStatinsStroke severitySymptomatic hemorrhagic transformation

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
07:34

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

3.6K

Related Experiment Videos

Last Updated: Apr 1, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
07:34

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

3.6K

Area of Science:

  • Neuroscience
  • Cardiology
  • Pharmacology

Background:

  • Statins possess neuroprotective properties, but their role in acute ischemic stroke (AIS) management remains unclear due to limited large-scale randomized trials.
  • Current clinical guidelines lack specific recommendations for initiating statin therapy in AIS patients.

Purpose of the Study:

  • To systematically review and meta-analyze the effects of statin therapy on outcomes in patients with AIS.

Main Methods:

  • Literature review of 70 articles, including 6 meta-analyses, focusing on prestroke and in-hospital statin use.
  • Meta-analysis of pooled estimates for initial stroke severity, functional outcomes, and short-term mortality.
  • Analysis of statin effects on imaging markers, including collaterals and reperfusion.

Main Results:

  • Prestroke statin use correlated with milder stroke severity, better functional outcomes, and reduced mortality.
  • In-hospital statin use was linked to improved functional outcomes and lower mortality.
  • Statin withdrawal was associated with poorer functional outcomes; however, statin use in thrombolysis patients showed benefits despite increased hemorrhagic transformation risk.

Conclusions:

  • Findings support statin use in AIS, primarily based on observational data.
  • Evidence suggests potential benefits in functional outcomes and mortality, but bias risk necessitates caution.
  • Large randomized clinical trials are crucial for definitive confirmation of statin efficacy and safety in AIS.